image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

UDG Healthcare

September 2017

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • UDG
  • Price:
  • 820p
Shares in UDG continue to make good progress, registering an all-time high of 866p. The group has also made two modest acquisitions (slotting into its Ashfield division). These include Cambridge BioMarketing for an initial US$30m (plus US$5m earn-out), a US-based healthcare communications agency specialising in orphan and rare disease drug launches, a market forecast to grow 11% compound annually between FY’17-FY’22 to US$209bn. The firm, based in Cambridge Massachusetts, provides a new platform for growth by enhancing UDG’s patient-focused communications programs and management hope to add value by further internationalising it, as well as scaling up using existing infrastructure.Earlier, UDG acquired US-based he ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X